Innoviva/$INVA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Innoviva
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
Ticker
$INVA
Sector
Primary listing
Employees
127
Headquarters
Website
Innoviva Metrics
BasicAdvanced
$1.3B
38.33
$0.53
0.39
-
Price and volume
Market cap
$1.3B
Beta
0.39
52-week high
$22.00
52-week low
$16.67
Average daily volume
764K
Financial strength
Current ratio
2.643
Quick ratio
2.377
Long term debt to equity
44.352
Total debt to equity
72.371
Interest coverage (TTM)
9.07%
Profitability
EBITDA (TTM)
206.856
Gross margin (TTM)
85.94%
Net profit margin (TTM)
10.44%
Operating margin (TTM)
48.81%
Effective tax rate (TTM)
41.04%
Revenue per employee (TTM)
$2,920,000
Management effectiveness
Return on assets (TTM)
8.83%
Return on equity (TTM)
5.60%
Valuation
Price to earnings (TTM)
38.327
Price to revenue (TTM)
3.459
Price to book
1.8
Price to tangible book (TTM)
2.57
Price to free cash flow (TTM)
6.523
Free cash flow yield (TTM)
15.33%
Free cash flow per share (TTM)
3.132
Growth
Revenue change (TTM)
12.02%
Earnings per share change (TTM)
-74.00%
3-year revenue growth (CAGR)
-2.85%
10-year revenue growth (CAGR)
30.51%
3-year earnings per share growth (CAGR)
-24.26%
10-year earnings per share growth (CAGR)
0.91%
What the Analysts think about Innoviva
Analyst ratings (Buy, Hold, Sell) for Innoviva stock.
Bulls say / Bears say
Innoviva’s Q2 2025 gross royalty revenue remained at $67.3 million, unchanged from a year earlier, highlighting the consistent performance of its GSK-related royalty portfolio.
The Innoviva Specialty Therapeutics division reported U.S. net product sales of $35.5 million in Q2 2025, up 54% year-on-year due to strong demand for GIAPREZA® and XACDURO®.
The FDA has accepted Innoviva’s NDA for zoliflodacin with Priority Review, with a PDUFA date of December 15, 2025. This potentially positions the company to launch the first new single-dose gonorrhea antibiotic in decades.
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
Innoviva Financial Performance
Revenues and expenses
Innoviva Earnings Performance
Company profitability
Innoviva News
AllArticlesVideos
Innoviva to Participate in Upcoming Investor Conferences
Business Wire·7 days ago
Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress
Business Wire·4 weeks ago
Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Innoviva stock?
Innoviva (INVA) has a market cap of $1.3B as of September 02, 2025.
What is the P/E ratio for Innoviva stock?
The price to earnings (P/E) ratio for Innoviva (INVA) stock is 38.33 as of September 02, 2025.
Does Innoviva stock pay dividends?
No, Innoviva (INVA) stock does not pay dividends to its shareholders as of September 02, 2025.
When is the next Innoviva dividend payment date?
Innoviva (INVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Innoviva?
Innoviva (INVA) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.